Merck Group & Moderna
5 shared events · Importance 6 · Last updated Aug 23, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Merck Group co-develops personalized mRNA cancer vaccines, including Intismeran, with Moderna, providing its immunotherapy Keytruda as a combination partner and sharing in development and commercialization. Merck also made an equity investment in Moderna in 2018.
Tech
Merck Group: Merck co-developed the vaccine and provided Pembrolizumab, the combination partner. Its shares rose about 10-12%, and the success helps Merck prepare for Pembrolizumab's patent expiration by expanding its cancer portfolio.
Moderna: Moderna is the developer of the mRNA vaccine and the primary beneficiary, with its stock surging over 120% and market cap increasing by nearly $40 billion. The trial success validates its mRNA platform beyond COVID-19 and could lead to a new revenue stream.
Aug 19, 2026 · 102 articles
Accidents
Merck Group: Merck Group's Ervebo vaccine is being deployed in the outbreak response, potentially increasing sales. However, its efficacy against the Bundibugyo strain is unproven, and the trial outcome will be critical.
Moderna: Authorized to begin Phase 1 trials for a Bundibugyo vaccine, using mRNA technology. Potential for significant revenue if successful.
Aug 01, 2026 · 295 articles
Accidents
Merck Group: Merck Group is the developer of Ervebo, the only approved Ebola vaccine, which is being deployed in the DRC outbreak. Its role is central, and successful cross-protection could expand its market and reputation.
Moderna: Moderna is developing an mRNA-based vaccine targeting the Bundibugyo strain, currently in clinical trials. Its progress could offer a more specific solution and enhance its vaccine portfolio.
Aug 22, 2026 · 8 articles
Accidents
Merck Group: Manufacturer of RVSV-ZEBOV vaccine, which is being considered for cross-protection trials. Its vaccine could play a role in the response, benefiting its reputation.
Moderna: Developed an mRNA-based Bundibugyo vaccine candidate, with Phase 1 trials starting in Canada. Its mRNA platform could offer a rapid response to emerging outbreaks.
Mar 09, 2018 · 543 articles
Business
Merck Group: Mentioned as a Benchling customer, indicating Benchling's credibility but not directly affected by this event.
Moderna: Mentioned as a Benchling customer, indicating Benchling's credibility but not directly affected by this event.
Aug 17, 2026 · 6 articles
90
Merck Group partnered with ModernaModerna Merck mRNA...
90
Moderna partnered with Merck GroupModerna Merck mRNA...
ERGEN INTELLIGENCE
Explore this relationship live
Track how Merck Group and Moderna interact across events, view sentiment trends, and discover connected entities.
Open Dashboard